Study:
A Phase II Evaluation of Belinostat (NSC #726630, IND #729990) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Rationale:
Belinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as carboplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving belinostat together with
carboplatin may kill more tumor cells.
Purpose:
This phase II trial is studying how well giving belinostat together with carboplatin works
in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube
cancer, or primary peritoneal cancer that did not respond to carboplatin or cisplatin.
Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving belinostat together with carboplatin may
kill more tumor cells
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Brenner Tumor
Fallopian Tube Cancer
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mixed Epithelial Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer |
Drug: belinostat
Drug: carboplatin |
Phase 2 |
Verified by
National Cancer Institute (NCI)
January, 2013
Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00993616
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
United States
Don Dizon., Principal Investigator